Ariel Hammerman
Ariel Hammerman
Health Technology Assessment Director, Medison Pharma
Verified email at
Cited by
Cited by
BNT162b2 vaccine booster and mortality due to Covid-19
R Arbel, A Hammerman, R Sergienko, M Friger, A Peretz, D Netzer, ...
New England Journal of Medicine 385 (26), 2413-2420, 2021
Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge
R Arbel, Y Wolff Sagy, M Hoshen, E Battat, G Lavie, R Sergienko, M Friger, ...
New England Journal of Medicine 387 (9), 790-798, 2022
Economic implications of 21‐gene breast cancer risk assay from the perspective of an Israeli‐managed health‐care organization
SH Klang, A Hammerman, N Liebermann, N Efrat, J Doberne, ...
Value in Health 13 (4), 381-387, 2010
Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years
R Arbel, R Sergienko, M Friger, A Peretz, T Beckenstein, S Yaron, ...
Nature medicine 28 (7), 1486-1490, 2022
Real-world effectiveness of a single dose of mpox vaccine in males
Y Wolff Sagy, R Zucker, A Hammerman, H Markovits, NG Arieh, ...
Nature Medicine 29 (3), 748-752, 2023
Effectiveness of the BNT162b2 vaccine after recovery from Covid-19
A Hammerman, R Sergienko, M Friger, T Beckenstein, A Peretz, D Netzer, ...
New England Journal of Medicine 386 (13), 1221-1229, 2022
Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: the real-life data
E Dudnik, M Moskovitz, S Daher, S Shamai, E Hanovich, A Grubstein, ...
Lung cancer 126, 217-223, 2018
Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study
R Arbel, A Peretz, R Sergienko, M Friger, T Beckenstein, H Duskin-Bitan, ...
The Lancet Infectious Diseases 23 (8), 914-921, 2023
Antipsychotics and diabetes: an age-related association
A Hammerman, J Dreiher, SH Klang, H Munitz, AD Cohen, M Goldfracht
Annals of Pharmacotherapy 42 (9), 1316-1322, 2008
Systemic therapy for psoriasis and the risk of herpes zoster: a 500 000 person-year study
G Shalom, D Zisman, H Bitterman, I Harman-Boehm, S Greenberg-Dotan, ...
JAMA dermatology 151 (5), 533-538, 2015
Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation
R Arbel, R Sergienko, A Hammerman, S Greenberg-Dotan, E Batat, ...
The American Journal of Medicine 132 (7), 847-855. e3, 2019
Bevacizumab for metastatic colorectal cancer: a global cost‐effectiveness analysis
DA Goldstein, Q Chen, T Ayer, KKW Chan, K Virik, A Hammerman, ...
The Oncologist 22 (6), 694-699, 2017
Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: a retrospective population-based cohort study
MH Ellis, T Neuman, H Bitterman, SG Dotan, A Hammerman, E Battat, ...
European journal of internal medicine 33, 55-59, 2016
Variability in outpatient antimicrobial consumption in Israel
O Nitzan, M Low, I Lavi, A Hammerman, S Klang, R Raz
Infection 38, 12-18, 2010
The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel
A Hammerman, S Greenberg-Dotan, I Feldhamer, Y Birnbaum, NI Cherny
Expert Review of Pharmacoeconomics & Outcomes Research 18 (1), 119-122, 2018
Trends in outpatient antibiotic use in Israel during the years 2000–2010: setting targets for an intervention
M Low, O Nitzan, H Bitterman, C Cohen, A Hammerman, N Lieberman, ...
Infection 41, 401-407, 2013
Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis
J Azuri, A Hammerman, E Aboalhasan, B Sluckis, R Arbel
Diabetes, Obesity and Metabolism 25 (4), 961-964, 2023
Effectiveness of a single-dose modified vaccinia Ankara in human monkeypox: an observational study
R Arbel, YW Sagy, R Zucker, NG Arieh, H Markovits, W Abu-Ahmad, ...
Research Square, 2022
Which is more valuable, longer survival or better quality of life? Israeli oncologists’ and family physicians’ attitudes toward the relative value of new cancer and congestive …
D Greenberg, A Hammerman, S Vinker, A Shani, Y Yermiahu, ...
Value in health 16 (5), 842-847, 2013
PCSK9 inhibitors may improve cardiovascular outcomes—Can we afford them?
R Arbel, A Hammerman, N Triki, D Greenberg
International Journal of Cardiology 220, 242-245, 2016
The system can't perform the operation now. Try again later.
Articles 1–20